Business Wire

FOURKITES

9.11.2022 09:01:33 CET | Business Wire | Press release

Share
FourKites Partners with Sony Network Communications Europe to Help Enterprise Shippers Deliver Exceptional Customer Experience

Today, leading supply chain visibility company FourKites announced a partnership with Sony Network Communications Europe. The partnership will integrate data from Visilion — Sony’s real-time cargo and asset tracking solution — with FourKites’ real-time, end-to-end supply chain visibility platform. This collaboration will help enterprise customers solve their most complex use cases. Now, customers will be able to view FourKites’ real-time data for shipments in transit and in the yard, together with Visilion’s granular real-time data on cargo location and condition to provide best-in-class estimated times of arrival (ETAs) and enhanced end-customer experiences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005131/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FourKites Partners with Sony Network Communications Europe to Help Enterprise Shippers Deliver Exceptional Customer Experience (Graphic: Business Wire)

Faced with ongoing global supply chain disruptions — including port congestion, port and rail strikes, global conflicts and more — businesses need more meaningful insights to mitigate preventable delays and damage, and to keep goods moving to their final destinations. Real-time visibility and actionable analytics regarding the location, temperature and status of shipments is critical, particularly for those in the Consumer Packaged Goods, Food & Beverage and Pharmaceutical industries, who ship products that require specific in-transit conditions to maintain quality.

“Businesses today require more high-quality, real-time supply chain data,” said Nimesh Patel, vice president of global alliances and partnerships at FourKites. “The Visilion solution from Sony provides an extra layer of granular data about the contents of containers and status of sensitive and/or temperature-controlled shipments. Our partnership will ensure that this data becomes more accessible than ever to businesses around the world.”

Visilion, Sony’s real-time cargo and asset tracking solution, offers industry-leading shock, tilt and temperature detection capabilities, among others, to ensure that goods are handled properly and maintained at the right temperature and humidity during transit, thereby mitigating losses. This functionality, combined with FourKites’ market-leading Dynamic ETA® across all modes, provides shippers with complete visibility into potential disruptions and product loss for goods in transit. In addition, FourKites’ international tracking capabilities, together with Visilion sensor data, provide an added dimension of granular visibility into ocean containers that often move through complicated, multi-stop journeys.

“FourKites’ shared commitment to industry-leading innovation, product quality and industry collaboration made them the obvious partner for us,” said Erik Lund, Head of Tracking Division, Sony Network Communications Europe. “We look forward to working together to provide our mutual customers with integrated supply chain data to fuel better decision-making and, ultimately, more efficient supply chain operations — in Europe and around the world.”

Over the last year, FourKites has experienced record growth in the European, Middle Eastern and African (EMEA) markets, achieving 97% growth in shipments YoY as of October 2022. The number of customers tracking loads with FourKites in EMEA grew 40% in the same time period, while the number of carriers tracking shipments grew by 50% in the same period.

About FourKites

Leading supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 210 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005131/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye